This Drug Discovery Stock Rises 50% in 1 Year: What Is Driving a Loss Making Biotech?
- September 17, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Suven Life Sciences: CMP Rs 340.75 (17 Sep 2026), 1-year return 49.94%, 52W range Rs 124.11 to Rs 403.35, market cap Rs 9,510 Cr, FY26 net loss Rs 276.34 Cr.
Quick Answer
Suven Life Sciences is the drug discovery stock that returned approximately 50% between 17 September 2025 and 17 September 2026, from Rs 227.26 to Rs 340.75. The gain came from clinical trial milestones and Rs 857.64 crore of fresh capital, not earnings. The company is loss making: FY26 net loss was Rs 276.34 crore on revenue of Rs 21.04 crore.
This drug discovery stock rose approximately 50% in one year without earning a rupee of profit. It closed at Rs 227.26 on 17 September 2025 and traded at Rs 340.75 on 17 September 2026, a verified gain of 49.94%, while the company reported a net loss of Rs 276.34 crore.
The company is Suven Life Sciences Ltd (NSE: SUVEN), a Hyderabad based clinical stage central nervous system research firm. It is not Suven Pharmaceuticals, the contract manufacturing business demerged from it and listed separately. This entity kept the new molecule assets, so it is a pure drug discovery stock that burns cash. The Suven Life Sciences share was among the stronger names on a screen of NSE small-cap stocks ranked by 1-year return, dated 17 September 2026.
Click Here – Get Free Investment Predictions
How Has This Drug Discovery Stock Performed Across Time Frames?
This drug discovery stock has gained about 50% over one year, roughly 148% over six months and around 329% over five years. The one month move is nearly flat. The Suven Life Sciences share price hit a 52-week high of Rs 403.35 on 1 September 2026 and has given back close to 15% since.
| Period | Start Date | Start Price (Rs) | 17 Sep 2026 (Rs) | Return |
|---|---|---|---|---|
| 1 Month | 17 Aug 2026 | 333.05 | 340.75 | 2.31% |
| 6 Months | 17 Mar 2026 | 137.38 | 340.75 | 148.03% |
| 1 Year | 17 Sep 2025 | 227.26 | 340.75 | 49.94% |
| 3 Years | 18 Sep 2023 | 74.35 | 340.75 | 358.30% |
| 5 Years | 17 Sep 2021 | 79.37 | 340.75 | 329.31% |
Returns are simple price changes, not annualised. The headline number hides a violent ride: this drug discovery stock fell to Rs 124.11 on 24 March 2026, down about 45% in six months, before nearly tripling from there.
Why Did This Drug Discovery Stock Rise 50%?
Five dated events in 2026 cut the risk around the lead drug candidate and answered the funding question that hangs over every loss making biotech. None involved profit or sales growth, which is normal at this stage.
1. Promoter Put Rs 425.70 Crore In on 6 March 2026
On 6 March 2026 the board allotted 3,17,68,764 shares at Rs 134 each to the promoter vehicle, Jasti Property and Equity Holdings Private Limited, on warrant conversion. That brought in Rs 425.70 crore and lifted the promoter stake from 66.06% to 70.15%. This drug discovery stock bottomed at Rs 124.11 eighteen days later.
2. Positive Phase 3 Safety Review on 4 June 2026
On 4 June 2026 the company reported a positive independent safety review and interim analysis from its global Phase 3 study of masupirdine, a 5-HT6 antagonist tested for agitation in Alzheimer’s dementia. The review, at the 50% completer mark, cleared the trial to continue unchanged. The share jumped about 13% in one session, from Rs 233.55 on 8 June to Rs 264.45 on 9 June.
3. Two Positive Read-Outs in Mid June 2026
On 16 June 2026 the company completed the first-in-human Phase 1 study of SUVN-I6107, a muscarinic M1 positive allosteric modulator, and later moved it into Phase 2. A day later it reported positive topline results from the Phase 2b trial of ropanicant in major depressive disorder, where the 45 mg dose beat placebo.
Two programmes clearing hurdles in one week is rare for an Indian drug discovery stock, and it turned a single bet on masupirdine into a pipeline with several shots on goal.
4. Rs 248.84 Crore Raised on 8 July 2026 Plus a Singapore Arm
On 8 July 2026 the board allotted 1,85,70,133 shares at Rs 134 each to seventeen non-promoter investors on warrant conversion, raising Rs 248.84 crore and cutting promoter holding to 65.47%. The company also set up Suven Neurosciences Pte. Ltd. in Singapore, a wholly owned development arm with committed capital of USD 100 million. This drug discovery stock climbed from Rs 273.85 on 1 July to Rs 327.60 on 3 July.
5. Phase 3 Enrollment Completed on 3 September 2026
On 3 September 2026 the company completed enrollment in the global Phase 3 masupirdine study with 424 patients randomised, above the 375 patient design target. Topline data is due by May 2027. This drug discovery stock touched its 52-week high two sessions earlier.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
The Financials Behind This Drug Discovery Stock
There is no way to dress this up. Suven Life Sciences is loss making and the losses are widening. June 2026 quarter revenue was Rs 11.09 crore against expenses of Rs 138.70 crore, a net loss of Rs 127.61 crore and the worst quarter on record.
| Quarter | Revenue (Rs Cr) | EBITDA (Rs Cr) | Net Loss (Rs Cr) | EPS (Rs) |
|---|---|---|---|---|
| Jun 2025 | 2.47 | -50.15 | -51.52 | -2.36 |
| Sep 2025 | 4.70 | -75.99 | -77.31 | -3.48 |
| Dec 2025 | 5.58 | -100.57 | -101.92 | -4.55 |
| Mar 2026 | 8.30 | -43.86 | -45.60 | -2.02 |
| Jun 2026 | 11.09 | -124.97 | -127.61 | -4.84 |
Revenue rose every quarter, from Rs 2.47 crore to Rs 11.09 crore, but the base is so small that margins lose meaning: operating margin in June 2026 was minus 3,500.84%. The spending is late stage trial cost, which is what a drug discovery stock should be doing.
| Financial Year | Revenue (Rs Cr) | EBITDA (Rs Cr) | Net Loss (Rs Cr) | EPS (Rs) |
|---|---|---|---|---|
| FY22 | 13.45 | -117.07 | -122.00 | -9.05 |
| FY23 | 21.99 | -111.44 | -118.27 | -5.42 |
| FY24 | 32.82 | -99.42 | -105.08 | -4.82 |
| FY25 | 17.55 | -154.88 | -160.75 | -7.37 |
| FY26 | 21.04 | -270.57 | -276.34 | -12.13 |
The FY26 loss is 72% wider than FY25 and more than double FY24. Cash used in operations was Rs 299.90 crore against Rs 155.31 crore. Anyone holding this drug discovery stock is funding a research programme, not buying earnings.
The balance sheet is at least clean for a drug discovery stock. FY26 total assets were Rs 624.21 crore against liabilities of Rs 32.81 crore, so equity is Rs 591.40 crore and debt to equity 0.03. A monitoring agency report dated 11 August 2026 confirmed no deviation in use of the Rs 857.64 crore raised.
Who Owns This Drug Discovery Stock?
Promoters own most of this drug discovery stock and institutional participation is thin. The promoter group held 70.08% in June 2026, falling to 65.47% in July after the non-promoter warrant conversion.
| Shareholder | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Promoters | 67.36% | 67.36% | 70.15% | 70.08% |
| FIIs | 1.17% | 1.07% | 0.91% | 0.56% |
| DIIs | 3.39% | 3.39% | 4.62% | 2.93% |
| Public | 28.07% | 28.18% | 24.32% | 26.42% |
Domestic institutions rose from 0.03% in June 2025 to 4.62% by March 2026, then trimmed to 2.93%. Foreign institutions cut their stake through the rally, from 1.17% to 0.56%. That is not what you see when professional money chases a re-rating in a drug discovery stock.
The shareholder count rose from 63,915 in March 2026 to 66,791 in June, so retail ownership grew as the price climbed. A promoter stake in the mid sixties also leaves a thin free float, which amplifies moves both ways.
Key Risks in This Drug Discovery Stock
Risks in this drug discovery stock are larger than in an ordinary small cap because the valuation rests on trial outcomes that have not happened yet. Six issues deserve attention.
Binary trial risk: Masupirdine topline data is due by May 2027. A failed Phase 3 read-out would remove the biggest reason this drug discovery stock re-rated, and Alzheimer’s programmes have a long record of late stage failure.
Cash burn and dilution: The June 2026 quarter alone consumed Rs 127.61 crore. Against Rs 857.64 crore raised, the runway is limited, so another raise in this drug discovery stock looks likely. The last two rounds were priced at Rs 134, far below today’s price.
No earnings support: With trailing EPS of minus Rs 12.47 there is no price to earnings ratio for this drug discovery stock. It trades at roughly 13.89 times a book value of Rs 24.23, and cannot be compared with the industry price to earnings ratio near 67.
Liquidity and volatility: With a market capitalisation near Rs 9,510 crore and promoter holding above 65%, traded volume in this drug discovery stock swings sharply. The share rose 19.6% on 18 May 2026 and fell 12.6% on 5 June. Position sizing matters more here than in a large cap.
Exchange query on price movement: On 6 February 2026 the exchange asked the company to explain movement in its price and volume. It replied that it had no undisclosed material information and blamed market speculation. A clean answer, but it confirms this drug discovery stock can move on sentiment alone.
No dividend, narrow revenue base: Dividend has been nil in each of the last five years, and revenue comes from a handful of research and grant lines, so one contract ending can halve the reported top line.
Download the Univest iOS App or Univest Android App to track the Suven Life Sciences share price live
Suven Life Sciences Share: Analyst View
Formal sell side coverage is very limited, which is normal for a pre-revenue biotech. No verified brokerage target is available for this drug discovery stock, so any figure circulating as a price target for the Suven Life Sciences share should be treated with caution unless you can trace it to a published note.
Analysts who follow the space watch four things: the May 2027 masupirdine read-out, the Phase 2 progression of SUVN-I6107, the global Phase 3 AWAKE study of samelisant in narcolepsy, and whether an out licensing deal is signed. The company held 62 partnering meetings at a San Diego biotech convention in June 2026 and showed five posters at a London Alzheimer’s conference in July, so a partner is the intended route to cash.
Suven Life Sciences Share Price Target
With no verified Suven Life Sciences share price target on record, the practical reference points for this drug discovery stock are traded levels: a 52-week high of Rs 403.35, about 18% above the current Suven Life Sciences share price, a 52-week low of Rs 124.11, and Rs 134 where insiders committed large sums in 2026.
| Reference Level | Price (Rs) | Distance From CMP |
|---|---|---|
| 52-Week High (1 Sep 2026) | 403.35 | 18.4% above |
| Current Market Price (17 Sep 2026) | 340.75 | Reference |
| Warrant Conversion Price | 134.00 | 60.7% below |
| 52-Week Low (24 Mar 2026) | 124.11 | 63.6% below |
| Book Value Per Share | 24.23 | 92.9% below |
Any Suven Life Sciences share price target built on discounted future drug sales is only as good as the approval probability behind it. For this drug discovery stock, waiting for the May 2027 data beats anchoring to the high.
Other Stocks to Track From the Same Return Screen
Beyond this drug discovery stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Entero Healthcare with a 1-year return of 48.61%, Neuland Labs at 41.50% and Diamond Power at 137.76%.
Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this drug discovery stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.
Conclusion
This drug discovery stock delivered a verified 49.94% gain in the year to 17 September 2026 on clinical milestones and a Rs 857.64 crore capital raise, not on business performance. FY26 revenue was Rs 21.04 crore against a net loss of Rs 276.34 crore.
The honest framing is that this drug discovery stock is a call option on a Phase 3 Alzheimer’s read-out due by May 2027, priced near Rs 9,510 crore. Investors comfortable with a binary outcome may size a small position and hold through the data. Everyone else can watch from the sidelines, and anyone acting on the Suven Life Sciences share should speak with a SEBI registered investment adviser.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which drug discovery stock rose 50% in 1 year?
Ans. Suven Life Sciences Ltd (NSE: SUVEN) is the drug discovery stock that gained approximately 49.94% between 17 September 2025 and 17 September 2026, from Rs 227.26 to Rs 340.75. It is a clinical stage central nervous system research company and is loss making.
Is Suven Life Sciences the same company as Suven Pharmaceuticals?
Ans. No, they are two separate listed companies. Suven Pharmaceuticals is the contract research and manufacturing business that was demerged and lists under its own symbol. Suven Life Sciences kept the new molecule assets, making it a drug discovery stock with almost no product revenue.
Why did the Suven Life Sciences share price rise in 2026?
Ans. Clinical milestones and fresh capital drove the move. The triggers were a positive independent Phase 3 safety review on 4 June 2026, positive results for ropanicant and SUVN-I6107 in mid June, and Rs 674.54 crore of warrant conversions in March and July 2026.
Is Suven Life Sciences profitable?
Ans. No, this drug discovery stock is loss making and the losses are widening. FY26 net loss was Rs 276.34 crore on revenue of Rs 21.04 crore, against Rs 160.75 crore in FY25. The June 2026 quarter loss of Rs 127.61 crore is the largest reported.
What is the 52-week high and low of Suven Life Sciences?
Ans. The 52-week high is Rs 403.35, touched on 1 September 2026, and the 52-week low is Rs 124.11, hit on 24 March 2026. This drug discovery stock was at Rs 340.75 on 17 September 2026.
What is the Suven Life Sciences share price target?
Ans. No verified brokerage Suven Life Sciences share price target is publicly available, because sell side coverage of this drug discovery stock is very limited. The reference points instead are the 52-week high of Rs 403.35, the low of Rs 124.11 and the Rs 134 warrant conversion price.
When will the Phase 3 Alzheimer’s results be reported?
Ans. Topline data from the global Phase 3 masupirdine study is expected by May 2027. Enrollment closed on 3 September 2026 with 424 patients randomised, above the 375 patient target. That read-out is the biggest event for this drug discovery stock.
Is this drug discovery stock safe for retail investors?
Ans. This drug discovery stock carries well above average risk because its valuation depends on unapproved drugs rather than earnings. There is no price to earnings ratio, it burned Rs 299.90 crore of operating cash in FY26, and a failed trial could reverse the rally.
